| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Psyence Biomedical invests $2.6m in PsyLabs after milestones met | 3 | Investing.com | ||
| 21.10. | Psyence Biomedical Ltd.: Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met | 1 | GlobeNewswire (USA) | ||
| 21.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 05.10. | Psyence Biomedical Ltd.: Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine | 369 | GlobeNewswire (Europe) | HIGHLIGHTS Texas Ibogaine Research Corporation ("TIRC"), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture... ► Artikel lesen | |
| 05.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 28.09. | Psyence BioMed unit signs term sheet for U.S. ibogaine rights | 2 | Investing.com | ||
| 28.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation | 425 | GlobeNewswire (Europe) | NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research... ► Artikel lesen | |
| 23.09. | Psyence BioMed investiert bis zu 5 Mio. USD in PsyLabs und plant Ibogain-Studie | 2 | Investing.com Deutsch | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Strategic Ibogaine Investment | 490 | GlobeNewswire (Europe) | Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential... ► Artikel lesen | |
| 23.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.09. | Psyence Biomedical Ltd.: Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development | 353 | GlobeNewswire (Europe) | HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion... ► Artikel lesen | |
| 08.09. | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | Small- & Micro Cap Investment | |||
| 18.08. | Psyence BioMed responds to Trump ibogaine announcement | 2 | Investing.com | ||
| 18.08. | Psyence BioMed positioniert sich nach Trump-Ankündigung zu Ibogain | 12 | Investing.com Deutsch | ||
| 18.08. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development | 347 | GlobeNewswire (Europe) | NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived... ► Artikel lesen | |
| 18.08. | Trump-Ankündigung zu Ibogain lässt Aktie von Psyence Biomedical haussieren | 2 | Investing.com Deutsch | ||
| 06.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 22.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,559 | -1,20 % | Valneva: Neue Langzeitdaten für Chikungunya-Impfstoff | Valneva hat neue Langzeitdaten zu seinem Chikungunya-Impfstoff IXCHIQ vorgelegt. Fünf Jahre nach einer einmaligen Impfung wiesen noch 94 Prozent der 221 auswertbaren Studienteilnehmer neutralisierende... ► Artikel lesen | |
| NOVAVAX | 7,200 | -1,77 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| PALATIN TECHNOLOGIES | 5,260 | 0,00 % | Earnings Call: Palatin Technologies verfehlt Markterwartungen deutlich - Aktie bricht um 14 % ein | ||
| OCUGEN | 0,681 | -3,27 % | Ocugen: Lizenzdeal mit Celairis - wie weit trägt die Aktie jetzt? | ||
| VIVORYON THERAPEUTICS | 0,694 | -4,67 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,272 | -3,89 % | 14 Tage oder 60 Monate Lagerung: Warum Gilead, Mesoblast und NurExone regenerative Therapien unterschiedlich verfügbar machen | ||
| SAREPTA THERAPEUTICS | 13,380 | -2,76 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,653 | -0,45 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| IMMUNITYBIO | 5,650 | +3,67 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,350 | -2,91 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| IMMATICS | 5,530 | -3,49 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| MYRIAD GENETICS | 5,010 | -0,20 % | Myriad Genetics, Inc.: Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth | ||
| MANNKIND | 3,649 | +2,16 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,120 | -9,49 % | Onco-Innovations Limited: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 10,265 | -0,10 % | JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer | Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields)... ► Artikel lesen |